作者: Jonathan E. Benjamin , Sally Arai
DOI: 10.1007/978-1-4419-6615-5_21
关键词:
摘要: Natural killer (NK) cell-based immunotherapy in cancer is gaining prominence yet still early its development as we learn more about NK cell biology and the molecular mechanisms that drive expansion, direct trafficking, determine target recognition. Clinical investigation of therapy has ranged from vivo modulation activity to ex purification/expansion adoptive transfer with modest results. Future trials will likely move toward refining current techniques expansion overcoming barriers engraftment host factors.